Même si les acteurs majeurs du développement musculaire ont été identifiés et les voies de transductions décrites, d’autres régulateurs restent encore à découvrir. Un crible ARNi pratiqué sur un modèle cellulaire couramment utilisé, la lignée myoblastique C2C12, a identifié 20 nouveaux gènes potentiellement impliqués dans la myogenèse in vitro. Au cours de ma thèse, deux de ces gènes ont été invalidés sur modèle souris en utilisant la technologie CRISPR/Cas9 pour valider in vivo leur implication. Pour l’un d’entre eux, seuls les animaux hétérozygotes ont pu être étudiés puisqu’une létalité précoce a été observée chez les homozygotes mutés. Aucune anomalie du développement musculaire n’a été mise en évidence. Une étude plus fine dans les premières phases du développement embryonnaire nous a permis de montrer le rôle indispensable de cette protéine précocement. L’étude du second gène – dont les analyses se poursuivent – semble confirmer in vivo le rôle de ce gène au cours de la myogenèse. Pour éviter la survenue de létalité embryonnaire et observer rapidement les effets de l’invalidation d’autres gènes, une technique de transgenèse somatique s’appuyant sur l’ARN interférence a été mis en place via l’injection de lentivirus contenant une cassette d’expression de shRNA directement dans le tibialis antérieur des souris. La validation de cette approche a été faite sur le gène de la myostatine, régulateur négatif du développement musculaire, et a montré une diminution de l’expression du gène associée à une augmentation de l’aire des fibres musculaires. La même approche appliquée à trois autres gènes renforce l’hypothèse de l’implication d’un des gènes dans le développement musculaire. Cette approche permet donc un crible rapide « in vivo » de gènes identifiés in vitro. Cependant, certaines améliorations doivent être apportées au protocole au regard des résultats obtenus. / Even if the major actors and transduction pathways of muscle development have been identified, there are still unknown regulatory factors. An in vitro RNAi screening performed on C2C12 myoblastic cells has permitted to identify 20 novel genes potentially implicated in myogenesis. During my thesis, two of these genes were invalidated on mouse model using CRISPR/Cas9 technology in order to confirm their implication in vivo. For the first gene, due to an early lethality occurring in homozygous mutated animals, only heterozygous animals were studied and there was no muscular development anomaly detected. A refined study of earlier stages of embryonic development permitted to show the essential role of the protein in these phases. The study of the second gene, still in progress, seems to confirm in vivo the implication of the gene on the myogenesis. In order to avoid embryonic lethality due to germline invalidation and to observe more rapidly the effects of gene invalidation in muscle, we developed a technique of somatic transgenesis based on RNA interference. Lentivirus containing a shRNA expression cassette was injected directly into the tibialis anterior of mice. We validated this approach on Myostatin gene, a well-known negative regulator of muscle development, showing that the decrease of Myostatin gene expression was associated to an increase of muscle fibers area. The same approach was used with three genes and support the hypothesis of the implication of one of them in muscle development. Thus, this approach allows a rapid “in vivo” screening of in vitro identified genes. Nonetheless, some improvements should be brought on the protocol according to the first results.

Chez les métazoaires, les cellules spécialisées se caractérisent par la sortie du cycle cellulaire alors que les cellules souches et progénitrices se caractérisent par un intense potentiel d'auto-renouvellement, lequel est perdu durant la différenciation. L'auto-renouvellement est contrôlé par une combinaison de facteurs intrinsèques et extrinsèques qui déclenchent une prolifération cellulaire équilibrée. Dans ce contexte, nous avons montré que le knock-out des facteurs de transcription MafB et c-Maf dans les monocytes, résulte en une expansion prolongée des monocytes et macrophages matures en culture, sans aucun signe de perte du phénotype différencié ou de la fonction. Etant donné que les macrophages sont impliqués dans la majorité des maladies dégénératives, les maladies inflammatoires ainsi que la biologie du cancer, l'amplification de macrophages consisterait en un atout considérable pour les applications thérapeutiques. Dans cette optique, et comme les macrophages sont également connus pour promouvoir le développement tumoral, nous avons étudié le comportement des macrophages Maf-DKO dans le contexte tumoral. Initialement, nous avons montré que les macrophages Maf-DKO sont capables d'empêcher l'installation de la tumeur ainsi que de réduire une masse tumorale établie, et ce indépendamment du model tumoral étudié. Ceci consiste en une nouvelle approche thérapeutique contre le cancer. Nous nous sommes ensuite intéressés à fournir une « preuve de principe » quant à la prolifération des monocytes humains après inhibition de l'expression des gènes MafB et c-Maf humains et à étudier leur potentiel dans des applications thérapeutiques. / In metazoans, specialized cells are typically withdrawn from the cell cycle, whereas stem cells and progenitor cells have extensive self-renewal potential that is usually lost on differentiation. Self-renewal is controlled by a combination of cell-intrinsic and extrinsic signals that trigger balanced cellular proliferation. In this context, we previously reported that the knock-out of two monocytic transcription factors, MafB and c-Maf, enables extended expansion of mature monocytes and macrophages in culture without loss of differentiated phenotype and function. As macrophages are involved in degenerative diseases, inflammatory diseases and cancer biology, amplified macrophages may provide potential therapeutic applications. In this context and since macrophages are also known to enhance tumor development, we aim to investigate Maf-DKO macrophages behavior in a tumor context Initially, we have shown that regardless of tumor model (ID8 ovarian carcinoma or B16 melanoma), Maf-DKO macrophages have the ability to prevent tumor growth and reduce established tumor mass in tumor bearing mice. The potential provides a novel therapeutic approach for cancer cell therapies. Next we aimed to provide a proof of principle for the amplification of human monocytes by the inhibition of MafB/c-Maf genes and to investigate their potential in therapeutic applications. So far, we have shown that the down-regulation of MafB and c-Maf in human monocytes results in a colony formation in semi-solid medium, reflecting that the knock down of MafB and c-Maf results in proliferative advantage.

<p>Eukaryotic Topoisomerase 2 is an essential enzyme that solves DNA topological problems such as DNA knotting, catenation, and supercoiling. It alters the DNA topology by introducing transient double strand break in one DNA duplex as a gate for the passage of another DNA duplex. Two different aspects of studies about eukaryotic Topoisomerase 2 will be covered in this thesis. In the first half of the thesis, we investigated conformational changes of human Topoisomerase 2&#61537; (hsTop2&#61537;) in the presence of cofactors and inhibitors. In the second half, we focused on an unknown regulatory function in the C-terminal domain (CTD) of Drosophila Topoisomerase 2 (Top2).</p><p>In the project of studying enzyme conformational changes, we adapted a previously developed methodology, Pulse-Alkylation Mass Spectrometry, with monobromobimane to study the protein dynamics of hsTop2&#61537;. Using this method, we captured the evidence of conformational changes in the presence of ATP and Mg2+ or the Top2 inhibitor, ICRF-193 which were not previously observed. Last, by using CTD truncated hsTop2&#61537;, the increasing reactivity of Cys427 suggested the CTD domain might be tethered adjacent to the core enzyme.</p><p>Following the study of enzyme conformational changes, we switched gear to examine an interaction between Drosophila Top2 and Mus101, homolog of human TopBP1. We first found that Mus101 interacts with CTD of Top2 in a phosphorylation-dependent manner. Next, in the co-immunoprecipitation and pull-down experiments using truncated or mutant Top2 with various Ser to Ala substitutions, we mapped the binding motif to the last amino acids of Top2 and identified that phosphorylation of Ser1428 and Ser1443 is important for Top2 to interact with the N-terminus of Mus101, which contains BRCT1/2 domains (BRCT, BRCA1 C-terminus). The binding affinity of the N-terminal Mus101 with a synthetic phosphorylated peptide covering the last 25 amino acids of Top2 (with pS1428 and pS1443) was determined by surface plasmon resonance with a Kd of 0.57 &#956;M. In an in vitro decatenation assay, Mus101 can specifically reduce the decatenation activity of Top2, and dephosphorylation of Top2 attenuates this response to Mus101. Next, we endeavored to establish a cellular system for testing the biological function of Top2-Mus101 interaction. Top2-silenced S2 cells rescued by Top2&#61508;20, truncation of 20 amino acids from the C-terminus of Top2, developed abnormally high chromosome numbers, which implies an infidelity in chromosome segregation during mitosis. Lastly, Top2-null flies rescued by Top2 with S1428A and S1443A were found to be viable but sterile. After investigating spermatogenesis, telophase of meiosis I was delayed, indicating Top2-Mus101 interaction is also important in segregating DNA in meiosis.</p> / Dissertation

Mémoire numérisé par la Division de la gestion de documents et des archives de l'Université de Montréal.

Mémoire numérisé par la Direction des bibliothèques de l'Université de Montréal.

Les gliomes sont les tumeurs cérébrales primitives les plus fréquentes de l’adulte. Le glioblastome (grade IV) en est la forme la plus agressive, caractérisé par sa résistance aux traitements actuels (chirurgie, chimiothérapie et radiothérapie). La mortalité de cette pathologie est quasi constante (survie médiane de 15 mois), ce qui justifie l’importance de découvrir de nouvelles cibles thérapeutiques. Le challenge est d'arriver à identifier des marqueurs spécifiques pour proposer un schéma thérapeutique alignant des stratégies de thérapies ciblées qui vont améliorer la prise en charge clinique, la survie globale et la survie sans progression des patients atteints de ces pathologies. Deux axes sont au centre des recherches fondamentales, translationnelles et cliniques. Le premier axe se définit autour du développement de molécules inhibitrices des voies de signalisation et le second autour du concept de cellules souches tumorales (CST) de glioblastomes (GBM) découvertes récemment dans le cerveau et qui révolutionnent la conception de la transformation tumorale.ASPM (Abnormal Spindle Like Microcéphaly Associated) est une cible candidate pertinente susceptible de participer au développement des gliomes (Horvath et al., 2007 ; Hagmann et al., 2008). Cette protéine régule la prolifération des neuroblastes, elle est fortement exprimée au stade embryonnaire, mais, reste faiblement exprimée dans le cerveau adulte. Par ailleurs, ASPM est impliquée dans divers processus de cancérisation (surexprimée dans les cancers du sein, du foie et du cerveau…), toute fois, le mécanisme responsable de cette dérégulation n’est pas encore bien caractérisé.Nos études menées sur une série de 169 gliomes humains, sélectionnés à partir de notre cohorte de patients, montrent que le gène ASPM est un marqueur de la progression vers la malignité, les grades les plus élevés exprimant le plus fortement ASPM. En outre, nous avons également montré que le niveau des transcrits d’ASPM est augmenté dans les récidives de gliomes et qu’en in vitro, ASPM contrôle la formation des gliomasphères (CST de GBM) avec une augmentation de l’expression de ses transcrits dans les cultures in vitro au fil des passages. En continuité de ces observations, nous avons alors développé un sh-miR-RNA spécifique d’ASPM permettant l’extinction post-transcriptionnelle de ce gène. Les résultats obtenus in vitro montrent que la perte d’expression d’ASPM conduit à un arrêt de la prolifération et aboutit à une mort cellulaire massive.Actuellement, des modèles de greffe de gliomasphères chez la souris (orthotopique) sont en cours de développement pour confirmer les effets observés in vitro et vérifier in vivo la validité de notre approche thérapeutique. En perspective, nous tenterons d’étudier les effets du silencing d’ASPM sur la voie de signalisation la plus dérégulée (pRB / E2F ou PI3K / AKT). Enfin, nous étudierons le rôle potentiel de cette protéine dans le contrôle du cycle cellulaire, et, in fine la mise en évidence de ses partenaires… / Glioblastoma (GBM) is the most frequent and aggressive form of primary brain tumors in adults; it is characterized by its resistance to current treatments (surgery, chemotherapy and radiotherapy). The prognosis is grim with a median survival of only 15 months underlining the importance to develop new therapeutic strategies. The recent development of the “tumor stem cell” (TSC) concept in hemopathies has been secondarily applied to gliomas with the identification of subpopulations of GBM cells which express neural stem cell markers and fulfill the criteria for stemness. Some evidences also suggest that this subpopulation could play a primary role in resistance to radio- and chemotherapy.ASPM (Abnormal Spindle Like Microcephaly Associated) is a protein regulating the proliferation of neuroblasts, highly expressed in the embryonic stage but weakly expressed in the adult brain. Preliminary reports suggesting that it could be involved in the development of gliomas (Horvath et al., 2007, Hagemann et al., 2008) prompted us to analyze further the role of this protein, focusing on its potential as a relevant candidate therapeutic target. In a series of 175 gliomas samples of various grades, we found that ASPM mRNA expression was strongly correlated with increasing tumor grade. We also found that ASPM expression increased at recurrence when compared to the initial lesion. Subsequently, we could demonstrate in vitro and in vivo that ASPM expression also increased over serial passages in gliomaspheres and in a mouse glioma xenograft model. In a therapeutic perspective, the effect of lentivirus-mediated shRNA post-transcriptional silencing of ASPM was evaluated in two different gliomasphere models and a dramatic proliferation arrest and cell death was observed. Taken together, these data suggest that ASPM is involved in the malignant progression of gliomas, possibly through expansion of a cancer stem cell compartment, and could be an attractive therapeutic target in glioblastoma multiforme.Another potential candidate tumor stem cell target in glioma is the sonic hedgehog pathway (hedgehog-Gli) which is required for GBM growth and stem cell expansion. In a collaborative study, it was found that NANOG, a transcription factor critically involved with self-renewal of undifferentiated embryonic stem cells, modulates gliomasphere clonogenicity, CD133+ stem cell behavior and proliferation. NANOG was regulated by hedgehog-Gli signalling and was essential for GBM tumourigenicity in orthotopic xenografts suggesting that it could also be a useful potential therapeutic target.Conclusions: Accumulating evidences suggest that tumor stem cells play an important role in the oncogenesis of gliomas and in their resistance to treatment. Our data support this concept and suggest that specific stemness markers may become useful targets to improve treatment of this devastating disease.

G-quadruplexes are non-canonical nucleic acid secondary structures of increasing biological and medicinal interest due to their proposed physiological functions in transcription, replication, translation and telomere biology. Aberrant G4 formation and stabilisation have been linked to genome instability, cancer and other diseases. However, the specific genes and pathways involved are largely unknown, and the work within this thesis aims to investigate this. Stabilisation of G4s by small molecules can perturb G4-mediated processes and initial studies suggest that this approach has chemotherapeutic potential. I therefore also aimed to identify cell genotypes sensitive to G4-ligand treatment that may offer further therapeutic opportunities. To address these aims, I present the first unbiased genome-wide genetic screen in cells where genes were silenced via short-hairpin RNAs (shRNAs) whilst being treated with either PDS or PhenDC3, two independent G4-stabilising small molecules. I explored gene deficiencies that enhance cell death (sensitisation) or provide a growth advantage (resistance) in the presence of these G4-ligands. Additionally, I present a validation screen, comprising hits uncovered via genome-wide screening, and also the use of this in another cell line of different origin. Sensitivities were enriched in DNA replication, cell cycle, DNA damage repair, splicing and ubiquitin-mediated proteolysis proteins and pathways. Ultimately, I uncovered four synthetic lethalities BRCA1, TOP1, DDX42, GAR1, independent of cell line and ligand. These were validated with three G4-stabilising ligands (PDS, PhenDC3 and CX-5461) using an independent siRNA approach. The latter siRNA methodology was used to screen 12 PDS derivatives with improved medicinal chemistry properties and ultimately identified SA-100-128, as a lead compound. The mechanism behind synthetic lethality with G4-stabilising ligands was explored further for DDX42, which I show has in vitro affinity for both RNA- and DNA-G4s and may represent a previously unknown G4-helicase. Also within this thesis, gene deficiencies that provided a growth advantage to PDS and/or PhenDC3 as uncovered by genome-wide and focused screening were explored. These showed enrichment in transcription, chromatin and lysosome-associated genes. The resistance phenotype of three gene deficiencies, TAF1, DDX39A and ZNF217 was further supported by additional siRNA experiments. Overall, I satisfied the primary aims and established many novel synthetic lethal and resistance interactions that may represent new therapeutic possibilities. Additionally, the results expand our knowledge of G4-biology by identifying genes, functions and subcellular locations previously not known to involve or regulate G4s.

CD4+ T cells are critical in the fight against parasitic, bacterial, and viral infections, but are also involved in many autoimmune and pathological disorders. Ligation of the T Cell Receptor (TCR) is the primary signal required for T cell activation proliferation, differentiation and cytokine release. Upon TCR activation, several kinases and adaptor proteins are assembled at the TCR/linker for activation of T cells (LAT) signaling complexes, a process indispensable for optimal signal transduction. One important group of proteins recruited to the TCR/LAT complexes is the GRB2 family of adaptors. Due to their role in mediating signaling complexes, the GRB2 family of adaptors are critical for development, proliferation, and survival of diverse cell types. These proteins have been linked to the initiation and progression of numerous pathological conditions including diabetes, asthma/allergy, and solid and hematopoietic malignancies. Therefore, it is essential to characterize and understand the complete functions of these proteins for the generation of safe and efficient targeting treatments for diseases mediated by these proteins. In T cells, GRB2 and its homologs, GADS and GRAP, are crucial for the propagation of signaling pathways through the TCR and adaptor protein LAT. These proteins recruit distinct sets of proline-rich ligands to LAT thereby inducing multiple signaling pathways such as MAP kinase activation, calcium influx and cellular adhesion. However, the role of GRB2 family members in controlling TCR and LAT mediated signaling in mature human T cells is not completely understood. Moreover, the relative role of GRB2 family members in the extent and timing of the recruitment of SH3 domain ligands to the LAT complex is unknown. Our hypothesis is that these proteins recruit distinct sets of ligands to the LAT complex that can drive differential downstream signaling events. As presented in CHAPTER III, we developed microRNA and shRNA targeting viral vectors to effectively inhibit the expression of GRB2 and GADS in human CD4+ T cells to examine the role of these adaptors in mature human T cells. We also established optimized protocols for high efficacy retro or lentiviral transduction of human T cell lines, activated and "hard-to-transduce" non-activated primary human CD4+ T cells. In CHAPTER IV, we demonstrate the requirement for GRB2 in TCR-induced IL-2 and IFN-γ release. The defects in cytokine release in the absence of GRB2 were attributed to diminished formation of LAT signaling microclusters, which resulted in reduced MAP kinase activation, calcium flux and PLC-γ1 recruitment to LAT signaling clusters. Overall, the data presented in this chapter demonstrate that the ability of GRB2 to facilitate protein clustering is as important in regulating TCR-mediated functions as its capacity to recruit effector proteins. This highlights that GRB2 regulates signaling downstream of adaptors and receptors by both recruiting effector proteins and regulating the formation of signaling complexes. In CHAPTER V, we describe the role for GADS in mediating TCR-induced IL-2 and IFN-γ production. GADS was critical for the recruitment of SLP-76 and PLC-γ1 to the LAT complex and subsequent calcium influx. We also show, in contrast to the current paradigm, that recruitment of GADS/SLP-76 complexes to LAT is not required for TCR-mediated adhesion and cytoskeletal arrangement. Overall, our studies reveal novel mechanisms for the role of GRB2 family members in TCR-mediated signaling. They also provide insight into the mechanisms that regulate growth factor, cytokine and insulin receptors. Importantly, studies presented in this thesis will help us understand the mechanisms of T cell activation and highlight potential new therapies for T cell-mediated diseases, including leukemia, lymphomas, autoimmune disorders and cardiovascular disease.

Les travaux présentés dans ce document retracent mes activités de Recherche dans le domaine de la Biologie Cellulaire et Moléculaire, qui m'ont conduit de la Toxicologie Génétique à la Radiobiologie. L'action des génotoxiques sur le patrimoine héréditaire a toujours constitué le fil conducteur de mes activités. A chaque étape de mon parcours, j'ai développé des modèles biologiques destinés à répondre à des thématiques bien précises. <br />Mon travail de recherche a commencé pendant deux ans à Rhône Poulenc (1985 1986) par le test de la réparation de l'ADN in vitro et in vivo (UDS ou unscheduled DNA synthesis) sur hépatocytes de rats Sprague Dawley et Fischer 344. Ce test de « dommages primaires » permet de prédire l'activité génotoxique des xénobiotiques. Dans l'approche in vivo, mon étude mettait en évidence l'importance du métabolisme intestinal dans l'activation métabolique de certains agents génotoxiques indirects (dérivés dinitrotoluène). J'ai ensuite débutée une approche plus fondamentale au CNRS (1988 1992). En utilisant les outils de la Génétique Moléculaire, j'ai créé un nouveau modèle cellulaire exprimant un système de régulation génique qui permet de détecter rapidement les agents modifiant le profil de méthylation de l'ADN au niveau des sites 5'CpG3'. Ces xénobiotiques, à l'origine des « épimutations » et de la dérégulation de l'expression de certains gènes, ont une contribution importante et souvent sous estimée dans la progression tumorale.<br />En 1992, je me suis orienté vers la Radiobiologie au DKFZ (Deutsches Krebsforschungszentrum ; Heidelberg, Allemagne) puis au CEA (LRA). Il s'agissait d'adapter à la Radiobiologie le modèle de culture de la peau humaine reconstituée in vitro, destiné auparavant à étudier la physiologie des kératinocytes normaux ou pathologiques. L'objectif était (i) d'irradier les spécimens de peau et d'étudier les effets d'une irradiation sur les kératinocytes et les fibroblastes), et (ii) de mimer in vitro la fibrose radioinduite. Ce modèle de culture alternatif prend en compte les interactions entre cellules épithéliales et mésenchymateuses. Au cours de ce travail, je me suis intéressé à la protéine humaine HSAkin17. Mon activité s'est alors recentrée sur cette protéine. Le développement de nombreuses approches cellulaires et moléculaires au laboratoire (LGR) nous a permis de mettre en évidence l'implication de cette protéine dans la réplication de l'ADN, notamment lorsque la progression des fourches de réplication est bloquée par des dommages non réparés de l'ADN. Nous avons démontré que cette protéine était un composant nécessaire au complexe de réplication de l'ADN et qu'elle avait une activité de reconnaissance des origines de réplication endogènes.<br />Depuis la fin 2003, j'ai développé et valider les vecteurs pEBVsiRNA pour une interférence ARN (RNAi) à très long terme (> 500 jours). Ce travail a été mené sur de nombreux gènes (110 gènes ciblés), essentiellement des gènes de la réparation de l'ADN. Un brevet a été déposé en 2005. Cette approche nous permet maintenant de travailler sur les interconnexions entre les mécanismes de réparation de l'ADN dans des lignées isogèniques. A ce jour, je suis le seul à proposer un tel modèle cellulaire cohérent avec un aussi grand nombre de clones stables, maintenus en culture aussi longtemps. La création de clones silencieux, stables à très long terme, m'a permis de participer à l'élaboration de nouveaux projets de Recherche dans le cadre de nombreuses collaborations, dont certaines seront énoncées dans ce rapport. Par ailleurs, ma démarche a aboutit à une valorisation industrielle.

Deregulation of platelet-derived growth factor receptor (PDGFR) signaling is a driving event in glioblastoma, promotes tumor progression epithelial to mesenchymal transition (EMT) in multiple cancers, modulates the tumor stroma to facilitate tumorigenesis and reduces tumor uptake of chemotherapeutics. Previous studies identified the 105 kDa isoform of ankyrin3 (Ank105) as a binding partner of the PDGFR signaling machinery and demonstrated that expression of Ank105 promoted PDGFR degradation (Ignatiuk et al., 2006)(Ignatiuk et al., 2006)(Ignatiuk et al., 2006). Receptor tyrosine kinases are targeted for degradation via endocytosis and ubiquitin-dependent trafficking to the lysosome. It was hypothesized that Ank105 promoted the constitutive degradation of the PDGFR and attenuation of PDGFR signaling by facilitating endocytosis of the PDGFR and targeting the PDGFR for lysosomal degradation via an ubiquitin-dependent mechanism. The studies in this thesis characterized the effects of Ank105 expression on PDGFR signaling and protein expression levels, determined the endocytic pathways involved in Ank105-mediated PDGFR degradation and studied the role of ubiquitin binding in Ank105 function. The most robust effect of Ank105 expression on the PDGFR was constitutive degradation as PDGFR protein expression levels in Ank105-expressing cells were significantly reduced compared to NIH 3T3 cells in the absence of PDGF ligand. Low constitutive PDGFR levels resulted in attenuated pro-proliferative AKT and mitogen-activated protein kinase (MAPK) signaling in response to ligand stimulation. To determine the endocytic requirements for Ank105-mediated constitutive PDGFR degradation, a constitutive PDGFR degradation assay was developed and the effects of several small molecule endocytosis inhibitors were evaluated. Additionally, the small molecule endocytosis inhibitors were validated by determining the effects of these inhibitors on low density lipoprotein (LDL) uptake and ligand-induced PDGFR degradation in Ank105-expressing cells. Both LDL uptake and ligand induced PDGFR degradation are known to proceed by a clathrin and dynamin dependent mechanism of endocytosis. In Ank105-expressing cells, both LDL uptake and ligand incuded PDGFR degradation were dependent upon clathrin and dynamin function. Interestingly, constitutive PDGFR degradation in Ank105-expressing cells was not dependent upon CME, but required dynamin activity. Expression of Ank105 may promote clathrin-independent, dynamin-dependent, constitutive endocytosis of the PDGFR. Additionally, acute inhibition of either lysosomal or proteasomal degradation strongly impaired constitutive PDGFR degradation, whereas ligand-induced PDGFR degradation was less sensitive to protein degradation inhibitors, while LDL uptake was unaffected. It was unclear if PDGFR was degraded in the proteasome or if the proteasome was involved in sorting of PDGFR to the lysosome for degradation. Ubiquitination of receptors is required to target them for degradation. Ank105 was assayed for the ability to interact with ubiquitin and ubiquitinated proteins. Interestingly, Ank105 bound ubiquitin in vitro via the spectrin binding domain and co-immunoprecipitated with several ubiquitinated proteins, suggesting a role for Ank105 in the sorting of ubiquitinated proteins for degradation. Furthermore, Ank105 co-immunoprecipitated with a number of high and low molecular weight proteins in the absence of PDGF stimulation. Identification of Ank105 binding partners would provide further insight in the mechanism of Ank105-mediated constitutive PDGFR degradation. In summary, Ank105 promoted the attenuation of PDGFR signaling via alteration of constitutive PDGFR endocytosis and targeting of constitutive PDGFR for degradation, potentially through interaction with ubiquitin and ubiquitinated proteins. Reduction of constitutive PDGFR levels in cancers with PDGFR driver mutations, acquired PDGF responsiveness and stromal expression of PDGFR, could significantly reduce tumor proliferation, tumorigenesis and increase effectiveness of chemotherapeutics.